SCHEMBL5223555

SCHEMBL5223555

CCCCC1(CCCC)CSc2cc(OC)ccc2N(c2ccc([N+](=O)[O-])cc2)C1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SNCA P37840 3/20 0.43
MEN1 O00255 6/20 0.40
KMT2A Q03164 6/20 0.40
MAPT P10636 6/20 0.39
LMNA P02545 5/20 0.38
HTT P42858 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
CRHBP P24387 1/20 0.37
GFER P55789 1/20 0.37
CRHR2 Q13324 1/20 0.37
ALDH1A1 P00352 3/20 0.37
HPGD P15428 1/20 0.37
ELANE P08246 1/20 0.37
KDM4E B2RXH2 1/20 0.36
CNR1 P21554 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
GPR55 Q9Y2T6 1/20 0.36
GAA P10253 1/20 0.35
RAB9A P51151 1/20 0.35
KCNJ1 P48048 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8014423 0.83 SLC6A2 (0.43) MAPTLMNAALDH1A1HPGDELANE
SCHEMBL5225561 0.81 MEN1 (0.39) SNCAMEN1KMT2AMAPTLMNA
SCHEMBL6843767 0.78 ELANE (0.40) MEN1KMT2AMAPTGFERELANE
SCHEMBL22286473 0.72 SLC6A2 (0.40) MAPTLMNAHTTSMN1; SMN2ALDH1A1
SCHEMBL22336274 0.72 SLC6A2 (0.38) MEN1KMT2AMAPTLMNASMN1; SMN2
SCHEMBL22286550 0.71 MAPK1 (0.37) MEN1KMT2AMAPTSMN1; SMN2ALDH1A1
SCHEMBL22286474 0.71 SLC6A2 (0.35) MEN1KMT2AMAPTSMN1; SMN2KDM4E
SCHEMBL19279084 0.70 SLC6A2 (0.40) MAPTLMNAHTTSMN1; SMN2ALDH1A1
SCHEMBL21586001 0.70 SLC6A2 (0.40) MAPTLMNAHTTSMN1; SMN2ALDH1A1
SCHEMBL22502854 0.70 SLC6A2 (0.34) ALDH1A1NPSR1GPR55SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1345918-B1 1,5 BENZOTHIAZEPINES AND THEIR USE AS ANTIHYPERLIPIDEMICS ASTRAZENECA AB (SE) 2007-04-18 EP disclosed
US-7192945-B2 Benzothiazepine derivatives ASTRAZENECA AB (SE) 2007-03-20 US disclosed
US-20040067933-A1 Chemical compounds ELOBIX AB (SE) 2004-04-08 US disclosed
EP-1345918-A1 CHEMICAL COMPOUNDS AstraZeneca AB (SE) 2003-09-24 EP disclosed
WO-2002050051-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2002-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040067933-A1 Chemical compounds SLC10A2, SLC10A1, ABCB11 SNCA 4757/4885MEN1 1329/4885KMT2A 2975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.